Last reviewed · How we verify
A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants
The objective of the study is to investigate the safety, pharmacokinetics, and pharmacodynamic effect of a single dose of MLN1202 in healthy Japanese male adults.
Details
| Lead sponsor | Takeda |
|---|---|
| Phase | Phase 1 |
| Status | WITHDRAWN |
| Start date | 2015-04 |
| Completion | 2015-11 |
Conditions
- Healthy Japanese and Caucasian Male Adults
Interventions
- MLN1202
- MLN1202 Placebo
Primary outcomes
- Number of Participants Reporting One or More Treatment-emergent Adverse Events — Up to Day 37
The adverse event is defined as any unfavorable and unintended sign, symptom, or disease that develops when a drug is administered, irrespective of the causal relationship to the drug.
Countries
Japan